Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
The pharmacokinetics of orally and intravenously administered valsartan were determined in two studies and it was found that absorption appeared to follow two first-order processes.
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
The rapid and fixed titration to high doses was associated with an increased risk of adverse events, which could potentially be reduced by adjusting concomitant antiepileptic medication and by using a slower, flexible OXC titration schedule.
Overview of the Clinical Pharmacokinetics of Oxcarbazepine
- G. Flesch
- Medicine, BiologyClinical drug investigation
In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), the elimination t½ of MHD is prolonged with a corresponding 2-fold increase in area under the concentration-time curve, so an increase in the dose of oxcarbazepine may be necessary to achieve similar plasma levels to those in adults.
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
- F. Waldmeier, G. Flesch, M. de Gasparo
- Medicine, BiologyXenobiotica; the fate of foreign compounds in…
The disposition of valsartan, a potent angiotensin II receptor antagonist, was investigated in six healthy male volunteers and it was indicated that at least 51% of the dose was absorbed.
Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine
- G. Flesch, C. Czendlik, D. Renard, P. Lloyd
- Medicine, ChemistryDrug Metabolism And Disposition
- 1 June 2011
This study was performed to characterize the disposition of the two enantiomers of M HD after oral and intravenous administration and to estimate the bioavailability of MHD after a single oral dose administration of OXC compared to a single intravenous treatment with MHD.
Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine
Results suggest that the kinetics of OCBZ should not be affected by impaired liver function, and linear and dose‐proportional kinetics with no autoinduction of metabolism simplify O CBZ dosage adjustment.
Prokaryotic hopanoids: the biosynthesis of the bacteriohopane skeleton. Formation of isoprenic units from two distinct acetate pools and a novel type of carbon/carbon linkage between a triterpene and…
Although an unknown biosynthetic pathway different from that usually proposed for isoprenoid biosynthesis can not be excluded, the former hypothesis explained all labelling patterns observed on the triterpenic skeleton.
Pharmacokinetics of pamidronate in patients with bone metastases.
- S. Leyvraz, U. Hess, P. Burckhardt
- Medicine, BiologyJournal of the National Cancer Institute
- 20 May 1992
The 1-hour infusion rate could be proposed as kinetically appropriate for the administration of pamidronate to patients with metastatic bone diseases.
Prokaryotic triterpenoids. A novel hopanoid from the ethanol-producing bacterium Zymomonas mobilis.
Among the triterpenoids of the bacterium Zymomonas mobilis a novel hopanoid, 32-oxobacteriohopane-33,34,35-triol beta-linked via its primary hydroxy group to glucosamine, has been isolated as a minor…
Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
- P. Müller, G. Flesch, M. de Gasparo, M. Gasparini, H. Howald
- MedicineEuropean Journal of Clinical Pharmacology
Valsartan is well tolerated and is devoid of effects on water, electrolyte and uric acid excretion at 200 mg per day in healthy normotensive volunteers, and indirect evidence of AT1 blockade by valsartans is demonstrated.